Drug intelligence / Profile preview

MAP46

Development stage: Unknown
Lead developer: Mapreg

Overview

MAP46 is an investigational drug initially developed by Mapreg SAS. As of March 2025, its highest global R&D status is Early Phase 1. The specific mechanism of action, molecular target(s), modality, and therapeutic area have not been publicly disclosed. No detailed information on its pharmacological class or clinical indications is available in the public domain at this time[1][4].

Beyond the preview

Go deeper on MAP46.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAP46.

Explore the full profile